Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR -JCARE 2025 First Quarterly Report

Time:2025-04-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Anuual General Meeting

Time:2025-04-24

Ad hoc announcement pursuant to Art. 53 LR -JCARE 2024 Annual Report

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR -JOINCARE Announcement on Re-appointment of The Auditor

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on the Resignation and Replacement of an Independent Director

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on the 2024 Profit Distribution Plan of the Company

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR- JOINCARE Announcement on the Capital Increase of The Holding Sub-Subsidiary

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2025 First Extraordinary General Meeting

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Progesterone Injection

Time:2025-03-24

Ad hoc announcement pursuant to Art. 53 LR-JOINCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2025-02-12

< 1234...12 >